The dormant in vivo phenotype of early stage primary human melanoma: Termination by overexpression of vascular endothelial growth factor

Angiogenesis

Volumn 2, Issue 3, 1998, Pages 203-217

  Bayko, Liisa ^a   Rak, Janusz ^a   Man, Shan ^a   Bicknell, Roy ^b   Ferrara, Napoleone ^c   Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GENENTECH INC   (United States)

Author keywords

Angiogenesis; Melanoma; Tumor dormancy; Tumor progression; VEGF VPF

Indexed keywords

MUS MUSCULUS;

EID: 0002244566     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009275307663     Document Type: Article

References (51)

1. Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells of the vertical growth phase: Similarities to metastatic cells. J Natl Cancer Inst 1985; 74, 283-289.
2. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9, 101-112.
3. Clark W. Tumor progression and the nature of cancer. Br J Cancer 1991; 64, 631-644.
4. Rodeck U, Herlyn M, Menssen HD, et al. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 1987; 40, 687-690.
5. Kath R, Rodeck U, Parmiter A, Herlyn M. Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediate lesions. Cancer Ther Control 1991; 1, 179-191.
6. Kobayashi H, Man S, MacDougall JR, et al. Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine resistant phenotype. Am J Pathol 1994; 144, 776-786.
7. Bani MR, Rak J, Adachi D, et al. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 1996; 56, 3075-3086.
8. Fridman R, Giaccone G, Kanemoto T, et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci (USA) 1990; 87, 6698-6702.
9. Fridman R, Kibbey MC, Royce LS, et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. J Natl Cancer Inst 1991; 83, 769-774.
10. Mehta RR, Graves JM, Hart GD, et al. Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res Treat 1993; 25, 65-71.
11. Pretlow TG, Delmoro CM, Dilley GG, et al. Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res 1991; 51, 3814-3817.
12. Bonfil RD, Vinyals A, Bustuoabad OD, et al. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 1994; 58, 233-239.
13. Vukicevic S, Kleinman HK, Luyten FP, et al. Identification of Multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 1992; 202, 1-8.
14. Klagsbrun M, Soker S. VEGF/VPF: the angiogenesis factor found? Curr Biol 1993; 3, 699-702.
15. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271, 603-606.
16. Dvorak HF, Brown LF, Detmar M, et al. Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146, 1029-1039.
17. Vinores SA, Kuchle M, Mahlow J, et al. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/ vascular permeability factor. Am J Pathol 1995; 147, 1289-1297.
18. Erhard H, Rietveld FJR, van Altena MC, et al. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1998; 7, S19-S26.
19. Weidner N. Curent pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36, 169-180.
20. Stein I, Neeman M, Shweiki D, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15, 5363-5368.
21. Ikeda E, Achen MG, Breier G, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270, 19761-19766.
22. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis. Nature 1992; 359, 843-845.
23. Potgens AJG, Lubsen NH, van Altena MC, et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146, 197-209.
24. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56, 172-181.
25. Ferrara N, Winer J, Burton T, et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 1993; 91, 160-170.
26. Cheng SY, Huang HJ, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93, 8502-8507.
27. Zhang H-T, Craft P, Scott PAE, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995; 87, 213
28. Minchenko A, Salceda S, Bauer T, et al. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994; 40, 35-39.
29. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362, 841-844.
30. Thomson W, Mackie RM. Comparison of five anti-melanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology. J Am Acad Dermatol 1989; 21, 1280-1284.
31. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1, 149-153.
32. Kerbel RS, Man MS, Dexter D. A model of human cancer metastasis: extensive spontaneous and artificial metastasis of a human pigmented and derived variant sublines in nude mice. J Natl Cancer Inst 1984; 72, 93-108.
33. Kerbel RS, Man MS. Single-step selection of unique human melanoma variants displaying unusually aggressive metastatic behavior in nude athymic mice. Invasion & Metastasis 1984; 4, 31-43.
34. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993; 190, 702-709.
35. Potgens AJG, van Altena MC, Lubsen NH, et al. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol 1996; 148, 1203-1217.
36. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82, 4-6.
37. Czubayko F, Schulte AM, Berchem GJ, et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci (USA) 1996; 93, 14753-14758.
38. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54, 3242-3247.
39. Rodeck U, Becker D, Herlyn M, et al. Basic fibroblast growth factor in human melanomas. Cancer Cells 1991; 3, 308-311.
40. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth [In Process Citation]. Nat Med 1997; 3, 887-893.
41. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69, 135-174.
42. Rak J, Filmus J, Finkenzeller G, et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14, 263-277.
43. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55, 4575-4580.
44. Volpert OV, Dameron KM, Bouck N, et al. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997; 14, 1495-1502.
45. Mazure NM, Chen EY, Yeh P, et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56, 3436-3440.
46. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci (USA) 1997; 94, 861-866.
47. Viloria-Petit AM, Rak J, Hung M-C, et al. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151, 1523-1530.
48. Cascinelli N, Bufalino R, Morabito A, et al. Results of an adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343, 913-914.
49. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial 1684. J Clin Oncol 1995.
50. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13, 2776-2783.
51. Schinkel AH, Wagenaar E, Mol CAAM, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97, 2517-2524.